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•	 Atypical	haemolytic	uraemic	syndrome	
(aHUS)	is	a	complement-mediated	disease	
associated	with	thrombocytopenia,	
haemolytic	anaemia	and	organ	dysfunction.1
•	 Renal	outcomes	are	poor	—	almost	half	of	
adults	with	aHUS	progress	to	end	stage	renal	
disease	(ESRD)	after	the	first	presentation.2
•	 Eculizumab,	a	terminal	complement	inhibitor,	
is	the	only	approved	treatment	for	aHUS.3,4
•	 The	efficacy	of	eculizumab	has	been	
demonstrated	in	two	prospective	clinical	
trials	involving	a	total	of	37	patients	aged	
≥12	years	with	aHUS.5	
•	 To	further	evaluate	data	from	two	
prospective	clinical	trials,5	by	comparing	
progression	to	ESRD	in	patients	before	and	
during	eculizumab	treatment.
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Patients
•	 Of	the	37	patients	involved	in	the	two	trials,	
8	(22%)	had	received	dialysis	within	the	8	
weeks	prior	to	the	first	dose	of	eculizumab.5
Renal	Failure	Events
The	supportive	care	and	eculizumab	
treatment	phases	included	32	and	33	patients,	
respectively	(Table 1).
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Study	Design
•	 Patients	enrolled	in	the	two	prospective	
clinical	trials5	were	analysed	for	progression	
to	a	renal	failure	(RF)	event.
•	 This	was	a	retrospective/prospective	post-
hoc	analysis,	evaluating	data	from	patients	
receiving	supportive	care	(pre-eculizumab)	
who	subsequently	initiated	eculizumab	
treatment.
	 –	 	Supportive	care	was	defined	as	plasma	
exchange/plasma	infusion,	dialysis	within	
the	8	weeks	prior	to	the	first	dose	of	
eculizumab,	and/or	kidney	transplant.
Analyses
•	 Any	patient	with	an	estimated	glomerular	
filtration	rate	(eGFR)	of	>15mL/min/1.73m2	
(chronic	kidney	disease	[CKD]	stage	2-4)	was	
eligible	for	an	RF	event
	 –	 	CKD	stages	2,	3	and	4	were	categorised	
as	eGFR	ranges	of	60-89,	30-59	and		
15-29	mL/min/1.73m2,	respectively.
	 –	 	Progression	to	a	RF	event	was	defined	as	
two	consecutive	eGFR	measurements		
<15	mL/min/1.73m2	(CKD	Stage	5).
•	 The	rate	of	RF	events	was	measured	per	90	
patient	days	pre-	and	post-treatment	with	
eculizumab.
•	 RF	incidence	rate	ratios	during	the	
supportive	care	and	eculizumab	treatment	
phases	were	calculated	using	a	negative	
binomial	regression	analysis.
•	 Kaplan-Meier	survival	curves	of	progression	
to	eGFR	of	<15mL/min/1.73m2	were	
calculated	for	the	pre-	and	post-eculizumab	
treatment	phases	and	stratified	for	patients	
in	CKD	Stages	2–4	at	baseline.
	 –	 	Equality	of	the	survival	curves	was	
assessed	using	log-rank	tests.
	 –	 	Hazard	ratios	(HRs)	of	ESRD	progression	
for	the	treatment	phase	relative	to	
supportive	care	phase	were	calculated	
from	Cox	proportional	hazard	models	with	
clustered	standard	errors.
	 –	 	The	analysis	was	not	designed	to	assess	
whether	renal	failure	was	acute	or	chronic.
METHODS
RESULTS
•	 In	patients	with	aHUS,	eculizumab	therapy	
reduces	the	number	of	RF	(renal	failure)	
events	and	the	rate	of	progression	to	
ESRD.
	 –	 	No	patients	with	Stage	2	or	3	CKD	at	
baseline	progressed	to	ESRD	during	
eculizumab	treatment.
•	 These	results	support	recommendations	
for	early	initiation	of	eculizumab,	to	
prevent	cumulative	kidney	damage	and	
progression	to	ESRD.
CONCLUSIONS
Presented at the 35th International Symposium on Intensive Care and Emergency Medicine, 17–20 March, 2015, Brussels, Belgium.
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Figure 1. RF Event Rates in the Supportive 
Care and Eculizumab Treatment Phases
CI,	confidence	interval;	RF,	renal	failure
aPer	90	days	of	eligibility.
Figure 2. Time to ESRD During Supportive Care and Eculizumab Treatment Phases
Progression	to	ESRD
•	 Analyses	of	the	time	to	ESRD	during	the	
supportive	care	and	eculizumab	treatment	
phases	(Figure 2)	showed	that:
	 –	 	With	eculizumab	treatment,	progression	
to	ESRD	(two	consecutive	eGFR	
measurements	<15mL/min/1.73m2)	was	
reduced	by	97%.
•	 With	supportive	care,	during	a	median	of	211	
days	(range	7–745),	13	(41%)	patients	had	a	
total	of	16	RF	events	(Table 1).
•	 On	eculizumab	treatment,	during	a	median	
of	924	days	(range	73–1254),	3	(9%)	patients	
had	a	total	of	5	RF	events	(Table 1).
	 –	 	The	RF	event	rate	per	90	days	of	eligibility	
was	92%	lower	during	eculizumab	
treatment	than	in	the	supportive	care	phase	
(0.364	vs	0.071;	P=0.001)	(Figure 1).
Table 1. Frequency of progression to a  
renal failure event in patients with eGFR 
>15mL/min/1.73m2 
Parameter Supportive 
care
(n=32)
During 
eculizumab 
treatment 
(n=33)
Days	with	eGFR	
>15mL/min/1.73m2,	
median	(range)
211	
(7–745)
924	
(73–1254)
RF	events	per	patient	
			Mean	(SD)	
			0,	n	(%)	
			1,	n	(%)	
			2,	n	(%)	
			3,	n	(%)
	
0.5	(0.7)	
19	(59)	
11	(34)	
1	(3)	
1	(3)
	
0.2	(0.5)	
30	(91)	
1	(3)	
2	(6)	
0
Total	number	of	RF	
events
16 5
eGFR,	estimate	glomerular	function;	RF,	renal	failure;	SD,	standard	deviation.	
Percentages	may	not	total	100	due	to	rounding.
	 	 •	 	HR for	progression	to	ESRD	for	
patients	on	eculizumab	compared	
to	supportive	care:	0.034,	P<0.001)	
(Figure 2A).
	 –	 	No	patients	who	initiated	eculizumab	in	
CKD	Stage	2	or	3	progressed	to	ESRD	
during	3	years	of	treatment	(Figures 2B 
and C).
	 –	 	For	patients	initiating	eculizumab	in	CKD	
Stage	4,	there	was	a	92%	reduction	in	
progression	to	ESRD	(HR	for	progression	
to	ESRD	compared	with	supportive	care:	
0.088,	P=0.0054)	(Figure 2D).
P329
P	values	were	determined	from	log-rank	tests	of	equality	of	survival	distributions.
CI,	confidence	interval;	CKD,	chronic	kidney	disease;	ESRD,	end-stage	renal	disease;	HR,	hazard	ratio.
